Background: Human Papillomavirus (HPV) types 6 and 11 are the causative agents of genital warts. HPV viruses come in over a hundred different varieties. The most common time for such skin-to-skin contact to occur is during sexual activity, where the risk of contracting HPV is highest. Cervical and anal cancer are caused by different kinds of HPV than genital warts. It's possible to be infected with multiple forms of HPV at once. For the treatment of warts immunotherapy could be used, which relies on the body's natural defenses to combat the infection and dampen down its activity. Immunotherapy can be administered orally, topically, intralesionally, or systemically. Objective: Assessment of role of different immunotherapy agents in anogenital warts management. Methods: Immunotherapy Agents, Anogenital Warts, and Management were all looked for in PubMed, Google scholar, and Science direct. References from relevant literature were also evaluated by the authors, but only the most recent or complete studies from 2006 to 2020 were included. Due to the lack of sources for translation, documents in languages other than English have been ruled out. Papers that did not fall under the purview of major scientific investigations, such as unpublished manuscripts, oral presentations, conference abstracts, and dissertations, were omitted. Conclusion: This review article aimed to throw the light on the effectiveness of immunotherapy, which varies greatly from patient to patient, but the procedure is very promising because it works outside the injected wart.